Psychopharmacological practice: The DSM versus the Brain

Mens Sana Monographs

Volumn 11, Issue 1, 2013, Pages 25-41

  Schwartz, Thomas ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Diagnostic systems; Neuroimaging; Neuroscience; Psychopharmacology

Indexed keywords

EID: 84876840307     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.109299     Document Type: Review

References (32)

1. Aizenstein HJ, Butters MA, Wu M, Mazurkewicz LM, Stenger VA, Gianaros PJ, et al. Altered Functioning of The Executive Control Circuit in Late-Life Depression: Episodic and Persistent Phenomena. Am J Geriatr Psychiatry 2009;17:30-42.
2. th Edition Text Revision. Washington DC: American Psychiatric Publishing; In press.
3. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study Am J Psychiatry 2010;167:281-8.
4. Carpenter WT Jr. The future of schizophrenia pharmacotherapeutics: Not so bleak. Mens Sana Monogr 2012;10:13-9.
5. Carter CS. Krug MK. The functional neuroanatomy of dread: Functional magnetic resonance imaging insights in to generalized anxiety disorder and its treatment. Am J Psychiatry 2009;166:263-4.
6. *D) study. Psychiatr Clin North Am 2003;26:457-94.
7. Filaković P, Petek A. Personalized Pharmacotherapy in Psychiatry. Psychiatr Danub 2009;21:341-6.
8. Greden JF. The burden of recurrent depression: Causes, consequences, and future prospects J Clin Psychiatry 2001;62:5-9.
9. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The Epidemiology of Major Depressive Disorder Results From the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
10. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348-60.
11. Keller MB, Shapiro RW. "Double depression": Superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry 1982;139:438-42.
12. Kim DH, Maneen MJ, Stahl SM. Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia. Neurotherapeutics 2009;6:78-85.
13. Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am 1996;19:85-102.
14. Regier DA, Narrow WE, Kuhl EA, Kupfer DJ. The conceptual development of the DSM-V. Am J Psychiatry 2009;111:645-50.
15. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33.
16. Schwartz TL. Psychopharmacology Today: Where are We and Where Do We Go from Here? Mens Sana Monogr 2010;8:6-16.
17. Schwartz TL, Rashid A. Augmentation and Combination Pharmacotherapy trends in major depressive disorder: Results of a brief survey of psychiatrists. Pharm Ther 2007;32:28-31.
18. Schwartz TL, Stahl SM. Vilazodone: A Brief Pharmacologic and Clinical Review of the Novel SPARI (Serotonin Partial Agonist and Reuptake Inhibitor) Therap Adv Psychopharmacol 2011;1:81-7.
19. Schwartz TL, Nihalani N. Neuronal Pathways Implicated in Executive Dysfunction. Clin Neuropsychiatry 2011;2:1-7.
20. Stahl SM. How to dose a psychotropic drug: Beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand 2010;122:440-1.
21. Stahl SM. Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology. Neuropsychopharmacology 2010;35:1413-4.
22. th ed. Cambridge: Cambridge University Press; 2013.
23. Stahl SM. Symptoms to Circuits, Part 1. J Clin Psych 2003;64:1282-3.
24. Stahl SM. Deconstructing psychiatric disorders, Part 1: Genotypes, symptom phenotypes, and endophenotypes. J Clin Psych 2003;64:982-3.
25. Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: A novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psych 2003;64:6-17.
26. Stahl SM. The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectrums 2007;12:583-8.
27. th ed. Cambridge: Cambridge University Press; 2011.
28. Stahl SM. Enhancing outcomes from major depression: Using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 2010;15:79-94.
29. *D (Sequenced Treatment Alternatives to Relieve Depression). Available From: http://www.nimh.nih.gov/trials/practical/stard/ index.shtml. [Last accessed 2012 Sep 19].
30. Sussman N. Translating Science Into Service: Lessons Learned From the Sequenced Treatment Alternatives to Relieve Depression. Prim Care Companion J Clin Psychiatry 2007;9:331-7.
31. World Health Report. Message from the Director-General. 2001. Available from: http://www.who.int/whr/2001/dg-message/en [Last accessed 2012 Sep 19].31.
32. Zeng LL, Shen H, Liu L, Wang L, Li B, Fang P, et al. Identifying major depression using whole-brain functional connectivity: A multivariate pattern analysis. Brain 2012;135:1498-507.